Siemens Enters into Master Agreement with Pfizer

Siemens HealthcareSiemens Healthcare Diagnostics Inc. has entered into a master collaboration agreement with Pfizer Inc. to design, develop and commercialize diagnostic tests for therapeutic products across Pfizer's pipeline. Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies and, potentially, eventual global commercialization with Pfizer products.

The partnership will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories and point-of-care settings (including clinics and physician offices) to help enable diagnostics development.

"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, Senior Vice President and Worldwide Head of Development Operations at Pfizer. "This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs."

Companion diagnostic tests are clinical tests linked to a specific drug or therapy intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.

"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," commented Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare. "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and, together, shape the future of diagnostic medicine."

The Siemens Clinical Laboratory (SCL), a "high-complexity", cutting-edge testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under the master agreement.

Related news articles:

About Siemens Healthcare
The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source - from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 52,000 employees worldwide and operates around the world. In fiscal year 2013 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of 2.0 billion euros.

Most Popular Now

Welcome Evo, Generative AI for the Genom…

Brian Hie runs the Laboratory of Evolutionary Design at Stanford, where he works at the crossroads of artificial intelligence and biology. Not long ago, Hie pondered a provocative question: If...

Research Study Shows the Cost-Effectiven…

Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI. New study findings...

Remote Telemedicine Tool Found Highly Ac…

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...

Philips Aims to Advance Cardiac MRI Tech…

Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic announced a research collaboration aimed at advancing MRI for cardiac applications. Through this investigation, Philips and Mayo Clinic will look to...

Almost All Leading AI Chatbots Show Sign…

Almost all leading large language models or "chatbots" show signs of mild cognitive impairment in tests widely used to spot early signs of dementia, finds a study in the Christmas...

Deep Learning Model Accurately Diagnoses…

Using just one inhalation lung CT scan, a deep learning model can accurately diagnose and stage chronic obstructive pulmonary disease (COPD), according to a study published today in Radiology: Cardiothoracic...

Shape-Changing Device Helps Visually Imp…

Researchers from Imperial College London, working with the company MakeSense Technology and the charity Bravo Victor, have developed a shape-changing device called Shape that helps people with visual impairment navigate...

Bayer Acquires HiDoc Technologies and Ca…

Bayer is today announcing that it plans to acquire HiDoc Technologies GmbH in the first quarter of 2025 and to start commercialization of the digital health application, Cara Care®. Cara...

AI-Based Chatbot Created for Bioimage An…

Scientists from Universidad Carlos III de Madrid (UC3M), together with a research team from Ericsson and the KTH Royal Institute of Technology in Sweden, have developed an artificial intelligence-based software...

Analyzing Multiple Mammograms Improves B…

A new study from Washington University School of Medicine in St. Louis describes an innovative method of analyzing mammograms that significantly improves the accuracy of predicting the risk of breast...

Emotional Cognition Analysis Enables Nea…

A joint research team from the University of Canberra and Kuwait College of Science and Technology has achieved groundbreaking detection of Parkinson's disease with near-perfect accuracy, simply by analyzing brain...